View in EDS HTML Full Text PDF Full Text

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.

Saved in:
Bibliographic Details
Title: Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
Authors: Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Marvin-Peek J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kornblau S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McCue D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Burger J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haddad F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bose P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Swaminathan M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Brandt M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Source: Cancer [Cancer] 2025 Jan 01; Vol. 131 (1), pp. e35662. Date of Electronic Publication: 2024 Nov 25.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39584789
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jen+WY%22">Jen WY</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Marvin-Peek+J%22">Marvin-Peek J</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Kantarjian+HM%22">Kantarjian HM</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Alvarado+Y%22">Alvarado Y</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Borthakur+G%22">Borthakur G</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Jabbour+E%22">Jabbour E</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Wierda+W%22">Wierda W</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Kadia+TM%22">Kadia TM</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Daver+NG%22">Daver NG</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22DiNardo+CD%22">DiNardo CD</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Short+NJ%22">Short NJ</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Jain+N%22">Jain N</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Ferrajoli+A%22">Ferrajoli A</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Kornblau+S%22">Kornblau S</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Yilmaz+M%22">Yilmaz M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Ohanian+M%22">Ohanian M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22McCue+D%22">McCue D</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Burger+J%22">Burger J</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Hammond+D%22">Hammond D</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Patel+K%22">Patel K</searchLink>; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Issa+GC%22">Issa GC</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Pemmaraju+N%22">Pemmaraju N</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Sasaki+K%22">Sasaki K</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Maiti+A%22">Maiti A</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Abbas+HA%22">Abbas HA</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Chien+K%22">Chien K</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Takahashi+K%22">Takahashi K</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Haddad+F%22">Haddad F</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Bose+P%22">Bose P</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Masarova+L%22">Masarova L</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Montalban-Bravo+G%22">Montalban-Bravo G</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Swaminathan+M%22">Swaminathan M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Brandt+M%22">Brandt M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Pierce+S%22">Pierce S</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Garcia-Manero+G%22">Garcia-Manero G</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Ravandi+F%22">Ravandi F</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2025 Jan 01; Vol. 131 (1), pp. e35662. <i>Date of Electronic Publication: </i>2024 Nov 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39584789
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.35662
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e35662
    Titles:
      – TitleFull: Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jen WY
      – PersonEntity:
          Name:
            NameFull: Marvin-Peek J
      – PersonEntity:
          Name:
            NameFull: Kantarjian HM
      – PersonEntity:
          Name:
            NameFull: Alvarado Y
      – PersonEntity:
          Name:
            NameFull: Borthakur G
      – PersonEntity:
          Name:
            NameFull: Jabbour E
      – PersonEntity:
          Name:
            NameFull: Wierda W
      – PersonEntity:
          Name:
            NameFull: Kadia TM
      – PersonEntity:
          Name:
            NameFull: Daver NG
      – PersonEntity:
          Name:
            NameFull: DiNardo CD
      – PersonEntity:
          Name:
            NameFull: Short NJ
      – PersonEntity:
          Name:
            NameFull: Jain N
      – PersonEntity:
          Name:
            NameFull: Ferrajoli A
      – PersonEntity:
          Name:
            NameFull: Kornblau S
      – PersonEntity:
          Name:
            NameFull: Yilmaz M
      – PersonEntity:
          Name:
            NameFull: Ohanian M
      – PersonEntity:
          Name:
            NameFull: McCue D
      – PersonEntity:
          Name:
            NameFull: Burger J
      – PersonEntity:
          Name:
            NameFull: Hammond D
      – PersonEntity:
          Name:
            NameFull: Patel K
      – PersonEntity:
          Name:
            NameFull: Issa GC
      – PersonEntity:
          Name:
            NameFull: Pemmaraju N
      – PersonEntity:
          Name:
            NameFull: Sasaki K
      – PersonEntity:
          Name:
            NameFull: Maiti A
      – PersonEntity:
          Name:
            NameFull: Abbas HA
      – PersonEntity:
          Name:
            NameFull: Chien K
      – PersonEntity:
          Name:
            NameFull: Takahashi K
      – PersonEntity:
          Name:
            NameFull: Haddad F
      – PersonEntity:
          Name:
            NameFull: Bose P
      – PersonEntity:
          Name:
            NameFull: Masarova L
      – PersonEntity:
          Name:
            NameFull: Montalban-Bravo G
      – PersonEntity:
          Name:
            NameFull: Swaminathan M
      – PersonEntity:
          Name:
            NameFull: Brandt M
      – PersonEntity:
          Name:
            NameFull: Pierce S
      – PersonEntity:
          Name:
            NameFull: Garcia-Manero G
      – PersonEntity:
          Name:
            NameFull: Ravandi F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2025 Jan 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 131
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1